Inactief instrument

Andere talen Plicit Capital Corp Toronto S.E.

Aandelen

PLPh

CA7291431079

slotkoers Toronto S.E. Andere beurzen
-	-

12/06	Telo Genomics Corp. Kondigt de resultaten aan van de ontwikkeling, validering en implementatie van zijn modules voor machinaal leren en kunstmatige intelligentie, die worden gebruikt in zijn TeloView myeloom diagnostische tests	CI
28/05	Telo Genomics Corp. Rapporteert winstresultaten voor het derde kwartaal en de negen maanden eindigend op 31 maart 2024	CI

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Telo Genomics Corp. Announces Results of Development, Validation and Implementation of its Machine Learning and Artificial Intelligence Modules, Use in its TeloView Myeloma Diagnostic Tests	12/06
Telo Genomics Presents Proprietary Artificial Intelligence Methodologies at ASCO 2024	12/06
Telo Genomics Corp. announced that it expects to receive CAD 0.6 million in funding	04/06
Telo Genomics Announces Publication of Results from Its Smoldering Myeloma Clinical Study in the American Journal of Hematology	30/05
Telo Genomics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	28/05
Telo Genomics Corp. Signs Collaboration Agreement with Emery Pharma	15/05
Telo Genomics and Emery Pharma Announce Collaboration	15/05
Telo Genomics Receives Accreditation from College of American Pathologists	10/04
Telo Genomics Receives Accreditation from College of American Pathologists	10/04
Telo Genomics Corp. Receives Accreditation from College of American Pathologists	10/04
Telo Genomics' MRD Clinical Trial Expands into Multi-Center Trial; Shares up 9.5%	02/04
Telo Genomics' Flagship MRD Clinical Trial Expands into Multi-Center Trial	02/04
Telo Genomics Corp. Announces Patient Recruitment for Its Minimal Respiratory Disease Clinical Trial Has Been Initiated, with Several Patient Samples Received and Processed to Date	02/04
Telo Genomics Corp. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	27/02
Telo Genomics Corp. Initiates MRD Clinical Trial for Multiple Myeloma Patients	13/02
Telo Genomics Initiates MRD Clinical Trial for Multiple Myeloma Patients	13/02
Telo Genomics Engages US Diagnostics Experts to Power Product Adoption in the US	30/01
Telo Genomics Corp. Announces Executive Changes	09/12
Telo Genomics Gears up for American Society of Hematology Conference	06/12
Telo Genomics Corp. Reports Earnings Results for the First Quarter Ended September 30, 2023	22/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Plicit Capital Corp Toronto S.E.

Aandelen

PLPh

CA7291431079

Andere talen

Filters